An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis

Brain

Volumn 121, Issue 5, 1998, Pages 967-975

  Sheean, Geoffrey L ^a   Murray, Nicholas M F ^a   Rothwell, John C ^b   Miller, David H ^a   Thompson, Alan J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Amino pyridines; Conduction block; Fatigue; K+ channel blocker; Multiple sclerosis

Indexed keywords

3,4 DIAMINOPYRIDINE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EXERCISE TEST; FATIGUE; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TRANSCRANIAL MAGNETIC STIMULATION;

4-AMINOPYRIDINE; ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; ELECTROMYOGRAPHY; EVOKED POTENTIALS, MOTOR; EXERCISE TEST; FATIGUE; FEMALE; HUMANS; MAGNETICS; MALE; MULTIPLE SCLEROSIS; POTASSIUM CHANNELS;

EID: 0031945246     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/121.5.967     Document Type: Article

References (42)

1. Bever CT Jr. The current status of studies of aminopyridines in patients with multiple sclerosis. [Review]. Ann Neurol 1994; 36 Suppl: S118-S121.
2. Bever CT, Leslie J, Camenga DL, Panitch HS, Johnson KP. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann Neurol 1990; 27: 421-7.
3. Bever CT Jr, Young D, Anderson PA, Krumholz A, Conway K, Leslie J, et al. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology 1994; 44: 1054-9.
4. Bever CT Jr, Anderson PA, Leslie J, Panitch HS, Dhib-Jalbut S, Khan OA, et al. Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology 1996; 47: 1457-62.
5. Bostock H, Sears TA and Sherratt RM. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres. J Physiol (Lond) 1981; 313: 301-15.
6. Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987; 14: 273-8.
7. Carter JL, Stevens JC, Smith B, Caselli RJ, Metcalf A, Windebank A, et al. A double-blind, placebo-controlled crossover trial of 3,4 diaminopyridine in the symptomatic treatment of multiple sclerosis [abstract]. Ann Neurol 1993; 34: 272-3.
8. Cohen RA, Fisher M. Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989; 46: 676-80.
9. Davis FA. Impairment of repetitive impulse conduction in experimentally demyelinated and pressure-injured nerves. J Neurol Neurosurg Psychiatry 1972; 35: 537-44.
10. Davis FA, Jacobson S. Altered thermal sensitivity in injured and demyelinated nerve. J Neurol Neurosurg Psychiatry 1971; 34:551-61.
11. 2 EDTA), and hyperventilation on visual and oculomotor signs in multiple sclerosis. J Neurol Neurosurg Psychiatry 1970; 33: 723-32.
12. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis [see comments]. Ann Neurol 1990; 27: 186-92. Comment in: Ann Neurol 1990; 28: 589.
13. Davis FA, Stefoski D, Rush J. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis [see comments]. Ann Neurol 1990; 27: 186-92. Comment in: Ann Neurol 1990; 28: 589.
14. Djaldetti R, Ziv I, Achiron A, Melamed E. Fatigue in multiple sclerosis compared with chronic fatigue syndrome: a quantitative assessment. Neurology 1996; 46: 632-5.
15. Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil 1984; 65: 135-8.
16. Geisser B. Multiple sclerosis: current concepts in management. Drugs 1985; 29: 88.
17. Jones RE, Heron JR, Foster DH, Snelgar RS, Mason RJ. Effects of 4-aminopyridine in patients with multiple sclerosis. J Neurol Sci 1983; 60: 353-62.
18. Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Neurol 1988; 45: 435-7.
19. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus [see comments]. Arch Neurol 1989; 46: 1121-3. Comment in: Arch Neurol 1989; 46: 841-2.
20. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus [see comments]. Arch Neurol 1989; 46: 1121-3. Comment in: Arch Neurol 1989; 46: 841-2.
21. Kujirai T, Caramia MD, Rothwell JC, Day BL, Thompson PD, Ferbert A, et al. Corticocortical inhibition in human motor cortex. J Physiol (Lond) 1993; 471: 501-19.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
23. Lloyd AR, Gandevia SC, Hales JP. Muscle performance, voluntary activation, twitch properties and perceived effort in normal subjects and patients with the chronic fatigue syndrome. Brain 1991; 114: 85-98.
24. McDonald WI, Sears TA. The effects of experimental demyelination on conduction in the central nervous system. Brain 1970; 93: 583-98.
25. Miller RG, Moussavi RS, Green AT, Carson PJ, Weiner MW. The fatigue of rapid repetitive movements. Neurology 1993; 43: 755-61.
26. Murray NM. The clinical usefulness of magnetic cortical stimulation [editorial], Electroencephalogr Clin Neurophysiol 1992; 85: 81-5.
27. Murray NM, Newsom-Davis J. Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981; 31: 265-71.
28. Murray TJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1985; 12: 251-4
29. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 1994a; 51: 292-6.
30. Polman CH, Bertelsmann FW, de Waal R, van Diemen HA, Uitdehaag BM, van Loenen AC, et al. 4-aminopyridine is superior to 3,4-diaminopyridine in the treatment of patients with multiple sclerosis. Arch Neurol 1994b; 51: 1136-9.
31. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
32. Rasminsky M. The effects of temperature on conduction in demyelinated single nerve fibers. Arch Neurol 1973; 28:287-92.
33. Sheean GL, Murray NM, Rothwell JC, Miller DH, Thompson AJ. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 1997; 120: 299-315.
34. Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980; 283: 570-2.
35. Stefoski D, Davis FA, Faut M, Schauf CL. 4-aminopyridine improves clinical signs in multiple sclerosis. Ann Neurol 1987; 21: 71-1.
36. Stefoski D, Davis FA, Fitzsimmons WE, Luskin SS, Rush J, Parkhurst GW. 4-aminopyridine in multiple sclerosis: prolonged administration. Neurology 1991; 41: 1344-8.
37. Targ EF, Kocsis JD. 4-aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve. Brain Res 1985; 328: 358-61.
38. van der Kamp W, Maertens de Noordhout A, Thompson PD, Rothwell JC, Day BL, Marsden CD. Correlation of phasic muscle strength and corticomotoneuron conduction time in multiple sclerosis. Ann Neurol 1991; 29: 6-12.
39. van Diemen HA, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoom MJ, et al. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol 1992; 32: 123-30.
40. van Diemen HA, Polman CH, van Dongen MM, Nauta JJ, Strijers RL, van Loenen AC, et al. 4-aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J Neurol Sci 1993; 116: 220-6.
41. Watson CW. Effect of lowering body temperature on the symptoms and signs of multiple sclerosis. N Engl J Med 1959; 261: 1253-9.
42. Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992; 42: 1468-71.